## 2-(1H-indol-3-ylthio)acetic acid: A molecule with potential
2-(1H-indol-3-ylthio)acetic acid, also known as **Indomethacin**, is a nonsteroidal anti-inflammatory drug (NSAID) with a complex chemical structure featuring an indole ring system.
**Why is it important for research?**
Indomethacin has several important applications in research, stemming from its anti-inflammatory properties and its role as a model compound:
* **Pharmacological research:** Indomethacin is widely used in preclinical and clinical studies to investigate the mechanisms of inflammation and the effectiveness of new anti-inflammatory treatments. Its well-characterized properties and clinical use make it a valuable tool for understanding how inflammation works and for testing the efficacy of new drug candidates.
* **Understanding of indole ring systems:** The presence of the indole ring in its structure makes Indomethacin a valuable model compound for studying the chemistry and biology of indole derivatives. Researchers can use Indomethacin to investigate how the indole ring interacts with various biological targets, leading to a better understanding of the role of indole derivatives in various biological processes.
* **Investigating the role of COX enzymes:** Indomethacin is a known inhibitor of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes are key players in the production of prostaglandins, molecules involved in inflammation, pain, and fever. By studying Indomethacin's effects on COX enzymes, researchers can gain insight into the intricate pathways of inflammation and pain signaling.
* **Developing new drugs:** The success of Indomethacin as a drug has inspired the development of new NSAIDs and other drugs with similar mechanisms of action. Researchers continue to explore and modify the indole ring structure of Indomethacin to create new, more potent, and more specific anti-inflammatory agents.
**Important to note:**
While Indomethacin has been a valuable research tool, it also has significant side effects. These include gastrointestinal problems, cardiovascular issues, and potential for liver damage. Its use in clinical practice has decreased due to the availability of newer, safer NSAIDs.
Despite its side effects, 2-(1H-indol-3-ylthio)acetic acid (Indomethacin) remains a cornerstone of research, providing valuable insights into inflammation, pain, and the development of new therapeutic agents.
| ID Source | ID |
|---|---|
| PubMed CID | 590707 |
| CHEMBL ID | 1892245 |
| CHEBI ID | 94115 |
| SCHEMBL ID | 3396574 |
| Synonym |
|---|
| HMS1675D08 |
| AKOS000442051 |
| smr000122976 |
| MLS000068615 , |
| OPREA1_523508 |
| (1h-indol-3-ylsulfanyl)-acetic acid |
| CBKINASE1_013006 |
| EU-0085245 |
| CBKINASE1_000606 |
| OPREA1_215628 |
| (1h-indol-3-ylsulfanyl)acetic acid |
| STK081188 |
| BRD-K74606027-001-01-7 |
| 2-(1h-indol-3-ylsulfanyl)acetic acid |
| F0907-1494 |
| SCHEMBL3396574 |
| 54466-88-5 |
| HMS2374P10 |
| (1{h}-indol-3-ylthio)acetic acid |
| 2-((1h-indol-3-yl)thio)acetic acid |
| cambridge id 5587525 |
| (1h-indol-3-ylsulfanyl)acetic acid # |
| acetic acid, 2-(3-indolylthio)- |
| CHEMBL1892245 |
| sr-01000522318 |
| DTXSID60343586 |
| CHEBI:94115 |
| (1h-indol-3-ylsulfanyl)-acetic acid, aldrichcpr |
| SR-01000522318-1 |
| Q27165865 |
| 2-(1h-indol-3-ylthio)acetic acid |
| indol-3-ylsulfanylacetic acid |
| 2-((1h-indol-3-yl)thio)aceticacid |
| EN300-235846 |
| Class | Description |
|---|---|
| indoles | Any compound containing an indole skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 112.2020 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| snurportin-1 | Homo sapiens (human) | Potency | 112.2020 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 95.2834 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1159537 | qHTS screening for TAG (triacylglycerol) accumulators in algae | 2017 | Plant physiology, Aug, Volume: 174, Issue:4 | Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| levoplast Levoplast: mixture of acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))-, castor oil, celluloidin, collodion & tannins | 2.15 | 1 | 0 | C-nitro compound | |
| hippuric acid hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591. N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl. | 2.15 | 1 | 0 | N-acylglycine | human blood serum metabolite; uremic toxin |
| xanthine 7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.. 9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated. | 2.15 | 1 | 0 | xanthine | Saccharomyces cerevisiae metabolite |
| atrolactic acid atrolactic acid: see also 3-isomer; RN given refers to parent cpd without isomeric designation; structure | 2.15 | 1 | 0 | 2-hydroxy monocarboxylic acid | |
| etofylline etofylline: etophyllin appeared once in PubMed: Wien Med Wochenschr. 1986 May 15;136(9):213-8 as a combination drug with theophylline (spelt without e, theophllin) | 2.15 | 1 | 0 | oxopurine | |
| n-acetyltryptophan N-acetyltryptophan : An N-acetylamino acid that is the N-acetyl derivative of tryptophan. | 2.15 | 1 | 0 | N-acetyl-amino acid; tryptophan derivative | metabolite |
| ethacridine Ethacridine: A topically applied anti-infective agent. | 2.15 | 1 | 0 | acridines | |
| altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine. | 2.15 | 1 | 0 | triamino-1,3,5-triazine | |
| 2,5-di-tert-butylhydroquinone 2,5-di-tert-butylbenzene-1,4-diol : A member of the class of hydroquinones that is benzene-1,4-diol substituted by tert-butyl groups at position 2 and 5. | 2.15 | 1 | 0 | hydroquinones | |
| cx546 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine: structure in first source | 2.15 | 1 | 0 | ||
| diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration. | 2.15 | 1 | 0 | ether; tertiary amino compound | anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative |
| diuron Diuron: A pre-emergent herbicide.. diuron : A member of the class of 3-(3,4-substituted-phenyl)-1,1-dimethylureas that is urea in which both of the hydrogens attached to one nitrogen are substituted by methyl groups, and one of the hydrogens attached to the other nitrogen is substituted by a 3,4-dichlorophenyl group. | 2.15 | 1 | 0 | 3-(3,4-substituted-phenyl)-1,1-dimethylurea; dichlorobenzene | environmental contaminant; mitochondrial respiratory-chain inhibitor; photosystem-II inhibitor; urea herbicide; xenobiotic |
| ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine | 2.15 | 1 | 0 | monocarboxylic acid | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic |
| ipriflavone ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women. | 2.15 | 1 | 0 | aromatic ether; isoflavones | bone density conservation agent |
| mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5. | 2.15 | 1 | 0 | aromatic ketone; benzimidazoles; carbamate ester | antinematodal drug; microtubule-destabilising agent; tubulin modulator |
| nocodazole [no description available] | 2.15 | 1 | 0 | aromatic ketone; benzimidazoles; carbamate ester; thiophenes | antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator |
| piribedil Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist. | 2.15 | 1 | 0 | N-arylpiperazine | |
| procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias. | 2.15 | 1 | 0 | benzamides | anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker |
| prometone prometone: structure. prometon : A methoxy-1,3,5-triazine that is 6-methoxy-1,3,5-triazine-2,4-diamine in which the one of the hydrogens of each amino group is substituted by an isopropyl group. | 2.15 | 1 | 0 | diamino-1,3,5-triazine; methoxy-1,3,5-triazine | environmental contaminant; herbicide; xenobiotic |
| propanil Propanil: A chlorinated anilide that is used as an herbicide.. propanil : An anilide resulting from the formal condensation of the carboxy group of propanoic acid with the amino group of 3,4-dichloroaniline. It is a herbicide used for the treatment of numerous grasses and broad-leaved weeds in rice, potatoes, and wheat. | 2.15 | 1 | 0 | anilide; dichlorobenzene | herbicide |
| sulfadimethoxine Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. | 2.15 | 1 | 0 | aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide | antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic |
| sulfamethazine Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position. | 2.15 | 1 | 0 | pyrimidines; sulfonamide antibiotic; sulfonamide | antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic |
| sulfathiazole Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position. | 2.15 | 1 | 0 | 1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide | antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic |
| testosterone [no description available] | 2.15 | 1 | 0 | 3-hydroxy steroid | androgen |
| 2-hydroxybenzylbenzimidazole 2-hydroxybenzylbenzimidazole: RN given refers to cpd without isomeric designation | 2.15 | 1 | 0 | ||
| etimizol Etimizol: A xanthine-related, putative nootropic drug. | 2.15 | 1 | 0 | ||
| nifenalol nifenalol: adrenergic beta-blocker with good antiarrhythmic properties; also tends to lower blood pressure & provide protection against angina; minor descriptor (75-86); on-line & INDEX MEDICUS search ETHANOLAMINES (75-86); RN given refers to parent cpd without isomeric designation | 2.15 | 1 | 0 | C-nitro compound | |
| bis(4-hydroxyphenyl)sulfone bis(4-hydroxyphenyl)sulfone: structure and RN in first source. 4,4'-sulfonyldiphenol : A sulfone that is diphenyl sulfone in which both of the para hydrogens have been replaced by hydroxy groups. | 2.15 | 1 | 0 | bisphenol; sulfone | endocrine disruptor; metabolite |
| 8-hydroxyquinoline-5-sulfonic acid 8-hydroxyquinoline-5-sulfonic acid: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| salicylanilide salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide. | 2.15 | 1 | 0 | benzanilide fungicide; salicylamides; salicylanilides | |
| 2-phenylbutyric acid 2-phenylbutyric acid : A monocarboxylic acid that is butyric acid substituted by a phenyl group at position 2. | 2.15 | 1 | 0 | benzenes; monocarboxylic acid | human xenobiotic metabolite |
| 4,4'-dimethoxybenzophenone 4,4'-dimethoxybenzophenone: structure in first source | 2.15 | 1 | 0 | ||
| 6-phenyl-1,3,5-triazine-2,4-diamine 6-phenyl-1,3,5-triazine-2,4-diamine: structure in first source | 2.15 | 1 | 0 | ||
| quinaldic acid [no description available] | 2.15 | 1 | 0 | quinolinemonocarboxylic acid | human metabolite; Saccharomyces cerevisiae metabolite |
| N-(2-methoxyphenyl)acetamide [no description available] | 2.15 | 1 | 0 | acetamides; methoxybenzenes | |
| fast red b Fast Red B: structure in first source. fast red B : An organosulfonate salt composed from 2-methoxy-4-nitrobenzene-1-diazonium and 5-sulfonaphthalene-1-sulfonate in a 1:1 ratio. Used for demostrating enterochromaffin in carcinoid tumours. | 2.15 | 1 | 0 | ||
| methylenebis(chloroaniline) Methylenebis(chloroaniline): Aromatic diamine used in the plastics industry as curing agent for epoxy resins and urethane rubbers. It causes bladder, liver, lung, and other neoplasms.. 4,4'-methylene-bis-(2-chloroaniline) : A chloroaniline that consists of two 2-chloroaniline units joined by a methylene bridge. | 2.15 | 1 | 0 | chloroaniline | metabolite |
| di-(4-aminophenyl)ether di-(4-aminophenyl)ether: structure | 2.15 | 1 | 0 | aromatic ether | |
| diphenylguanidine diphenylguanidine: vulcanization accelerator; RN given refers to parent cpd. 1,3-diphenylguanidine : Guanidine carrying a phenyl substituent on each of the two amino groups. It is used as an accelerator in the rubber industry. | 2.15 | 1 | 0 | guanidines | allergen |
| 4-Anilino-4-oxobutanoic acid [no description available] | 2.15 | 1 | 0 | anilide | |
| mephobarbital Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.. mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups. | 2.15 | 1 | 0 | barbiturates | anticonvulsant |
| etryptamine etryptamine: RN given refers to cpd without isomeric designation | 2.15 | 1 | 0 | indoles | |
| sulfacetamide [no description available] | 2.15 | 1 | 0 | ||
| cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94 | 2.15 | 1 | 0 | quinolines | |
| 2-aminobenzothiazole [no description available] | 2.15 | 1 | 0 | benzothiazoles | |
| carzenide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| nitrilotriacetic acid Nitrilotriacetic Acid: A derivative of acetic acid, N(CH2COOH)3. It is a complexing (sequestering) agent that forms stable complexes with Zn2+. (From Miall's Dictionary of Chemistry, 5th ed.) | 2.15 | 1 | 0 | NTA; tricarboxylic acid | carcinogenic agent; nephrotoxic agent |
| n-(2-cyanoethyl)-2-phenylethylamine N-(2-cyanoethyl)-2-phenylethylamine: prodrug of 2-phenylethylamine | 2.15 | 1 | 0 | ||
| cyclooctane [no description available] | 2.15 | 1 | 0 | ||
| triphenyltetrazolium chloride 2,3,5-triphenyltetrazolium chloride : An organic chloride salt having 2,3,5-triphenyltetrazolium as the counterion. | 2.15 | 1 | 0 | organic chloride salt | dye; indicator |
| 2,7-diacetylaminofluorene 2,7-diacetylaminofluorene: has been found to induce leukemia in animals; minor descriptor (75-84); on-line search 2-ACETYLAMINOFLUORENE/AA (75-84); Index Medicus search 2-ACETYLAMINOFLUORENE/AA (80-82), FLUORENES (75-79) | 2.15 | 1 | 0 | ||
| 3,4-pyridinedicarboxylic acid 3,4-pyridinedicarboxylic acid: structure in first source | 2.15 | 1 | 0 | pyridinedicarboxylic acid | |
| 4-(benzoylamino)-2-hydroxybenzoic acid 4-(benzoylamino)-2-hydroxybenzoic acid: Bepask is calcium salt | 2.15 | 1 | 0 | benzamides | |
| tropic acid tropic acid: acid moiety of ester alkaloids hyoscyamine & scopolamine; RN given refers to parent cpd with unspecified isomeric designation; structure. tropic acid : A 3-hydroxy monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a phenyl group, and one of the methyl hydrogens is substituted by a hydroxy group. | 2.15 | 1 | 0 | 3-hydroxy monocarboxylic acid | human xenobiotic metabolite |
| 8-hydroxy-7-iodo-5-quinolinesulfonic acid 8-hydroxy-7-iodo-5-quinolinesulfonic acid: used with iodine isotopes in radioisotope scanning; structure | 2.15 | 1 | 0 | hydroxyquinoline | |
| 1-acetylisatin 1-acetylisatin: structure in first source | 2.15 | 1 | 0 | indoledione | |
| 4-cumylphenol [no description available] | 2.15 | 1 | 0 | diarylmethane | |
| 5-methylisatin 5-methylisatin: structure in first source | 2.15 | 1 | 0 | ||
| 2-hydrazinobenzothiazole [no description available] | 2.15 | 1 | 0 | ||
| 1,2,3-trimethoxybenzene 1,2,3-trimethoxybenzene : A methoxybenzene that is benzene substituted by methoxy groups at positions 1, 2 and 3 respectively. | 2.15 | 1 | 0 | methoxybenzenes | plant metabolite |
| 2-amino-5-chlorobenzophenone 2-amino-5-chlorbenzophenone: structure given in first source | 2.15 | 1 | 0 | ||
| diphenamid diphenamid: do not confuse with anti-inflammatory agent difenpiramide; structure | 2.15 | 1 | 0 | diarylmethane | |
| 4-(4-nitrobenzyl)pyridine [no description available] | 2.15 | 1 | 0 | ||
| 5-methyl-3-phenylisoxazole-4-carboxylic acid 5-methyl-3-phenylisoxazole-4-carboxylic acid: has anti-tumor, antiviral, hypoglycemic, antifungal and anti-HIV activities; structure in first source | 2.15 | 1 | 0 | ||
| 2-acetylbenzofuran 2-acetylbenzofuran: structure in first source | 2.15 | 1 | 0 | ||
| pyrazon pyrazon: structure; do not confuse with phenazone which is a synonym to antipyrine. chloridazon : A pyridazinone that is pyridazin-3(2H)-one substituted by an amino group at position 5, a chloro group at position 4 and a phenyl group at position 2. | 2.15 | 1 | 0 | benzenes; organochlorine compound; primary amino compound; pyridazinone | environmental contaminant; herbicide; xenobiotic |
| 2-amino-5-nitrobenzophenone 2-amino-5-nitrobenzophenone: urinary metabolite of nitrazepam | 2.15 | 1 | 0 | ||
| (4-tert-Butyl-phenoxy)-acetic acid [no description available] | 2.15 | 1 | 0 | monocarboxylic acid | |
| lenacil lenacil: Russian drug. herbicide : A substance used to destroy plant pests.. lenacil : A cyclopentapyrimidine that is 6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione substituted by a cyclohexyl group at position 3. | 2.15 | 1 | 0 | cyclopentapyrimidine | agrochemical; environmental contaminant; herbicide; xenobiotic |
| chlordesmethyldiazepam [no description available] | 2.15 | 1 | 0 | benzodiazepine | |
| 2-amino-2',5-dichlorobenzophenone 2-amino-2',5-dichlorobenzophenone: structure given in first source | 2.15 | 1 | 0 | ||
| 2-(2'-hydroxyphenyl)benzimidazole 2-(2'-hydroxyphenyl)benzimidazole: structure in first source | 2.15 | 1 | 0 | ||
| 4-phthalimidobutyric acid 4-phthalimidobutyric acid: teratogen; RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| azabutyrone azabutyrone: Russian drug; RN given refers to parent cpd; structure | 2.15 | 1 | 0 | ||
| 2-(2-hydroxyphenyl)benzothiazole 2-(1,3-benzothiazol-2-yl)phenol : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by a 2-hydroxyphenyl group at position 2. | 2.15 | 1 | 0 | benzothiazoles; phenols | geroprotector |
| 4,5-dichlorocatechol [no description available] | 2.15 | 1 | 0 | ||
| n-butylbenzenesulfonamide N-butylbenzenesulfonamide: a neurotoxic plasticising agent. N-butylbenzenesulfonamide : A sulfonamide that is benzenesulfonamide substituted by a butyl group at the nitrogen atom. It has been isolated from the plant Prunus africana and has been shown to exhibit antiandrogenic activity. | 2.15 | 1 | 0 | sulfonamide | neurotoxin; plant metabolite |
| 3-phenoxybenzoic acid 3-phenoxybenzoic acid: metabolite associated with exposure to pyrethroid insecticides. 3-phenoxybenzoic acid : A phenoxybenzoic acid in which the phenoxy group is meta to the carboxy group. It is a metabolite of pyrethroid insecticides. | 2.15 | 1 | 0 | phenoxybenzoic acid | human xenobiotic metabolite; marine xenobiotic metabolite |
| 2-(2-hydroxyethylmercapto)benzothiazole 2-(2-hydroxyethylmercapto)benzothiazole: reaction product of 2-mercaptobenzothiazole, well-known rubber vulcanization accelerator; structure in first source | 2.15 | 1 | 0 | ||
| carboxin Carboxin: A systemic agricultural fungicide and seed treatment agent.. carboxin : An anilide obtained by formal condensation of the amino group of aniline with the carboxy group of 2-methyl-5,6-dihydro-1,4-oxathiine-3-carboxylic acid. A fungicide for control of bunts and smuts that is normally used as a seed treatment. | 2.15 | 1 | 0 | anilide fungicide; anilide; enamide; organosulfur heterocyclic compound; oxacycle; secondary carboxamide | antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor |
| meturin [no description available] | 2.15 | 1 | 0 | ||
| 2-bromo-N-phenylbenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 4-chlorohippuric acid 4-chlorohippuric acid: metabolite of zomepirac; RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| 4-chlorophenoxyacetic acid 4-chlorophenoxyacetic acid: RN given refers to parent cpd; structure. (4-chlorophenoxy)acetic acid : A chlorophenoxyacetic acid that is phenoxyacetic acid carrying a chloro substituent at position 4. | 2.15 | 1 | 0 | chlorophenoxyacetic acid; monochlorobenzenes | phenoxy herbicide |
| 2,5-dichloro-1,4-phenylenediamine 2,5-dichloro-1,4-phenylenediamine: structure in first source | 2.15 | 1 | 0 | ||
| metribuzin metribuzin : A member of the class of 1,2,4-triazines that is 1,2,4-triazin-5(4H)-one substituted by an amino group at position 4, tert-butyl group at position 6 and a methylsulfanyl group at position 3. | 2.15 | 1 | 0 | 1,2,4-triazines; cyclic ketone; organic sulfide | agrochemical; environmental contaminant; herbicide; xenobiotic |
| 2,5-dimethyl-3-furancarboxanilide 2,5-dimethyl-3-furancarboxanilide: structure | 2.15 | 1 | 0 | ||
| moricizine hydrochloride moricizine hydrochloride : A hydrochloride salt obtained from equimola amounts of moricizine and hydrogen chloride. | 2.15 | 1 | 0 | hydrochloride | anti-arrhythmia drug |
| 2-benzimidazolylguanidine 2-benzimidazolylguanidine: effects chloride efflux in tissue; RN given refers to parent cpd | 2.15 | 1 | 0 | aminoimidazole | |
| diflubenzuron Diflubenzuron: An insect growth regulator which interferes with the formation of the insect cuticle. It is effective in the control of mosquitoes and flies.. diflubenzuron : A benzoylurea insecticide that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 4-chlorophenyl group, and a hydrogen attached to the other nitrogen is replaced bgy a 2,6-difluorobenzoyl group. | 2.15 | 1 | 0 | benzoylurea insecticide; monochlorobenzenes | insect sterilant |
| pentafluorobenzoyl-n-phenylethylamine [no description available] | 2.15 | 1 | 0 | ||
| thidiazuron [no description available] | 2.15 | 1 | 0 | ureas | |
| phenthiazamine phenthiazamine: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| 5,5-diphenylbarbituric acid 5,5-diphenylbarbituric acid: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| 3-acetamidobenzoic acid N-acetyl-m-aminobenzoic acid: from Solanum laciniatum; structure in first source | 2.15 | 1 | 0 | ||
| dazoxiben hydrochloride [no description available] | 2.15 | 1 | 0 | ||
| succinylsulfanilamide [no description available] | 2.15 | 1 | 0 | ||
| benzylaminopurine benzylaminopurine: a plant growth regulator. N-benzyladenine : A member of the class of 6-aminopurines that is adenine in which one of the hydrogens of the amino group is replaced by a benzyl group. | 2.15 | 1 | 0 | 6-aminopurines | cytokinin; plant metabolite |
| ciprofloxacin hydrochloride anhydrous [no description available] | 2.15 | 1 | 0 | hydrochloride | antibacterial drug; antiinfective agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor |
| src-820 r [no description available] | 2.15 | 1 | 0 | ||
| n(4)-acetylsulfadiazine N(4)-acetylsulfadiazine: main metabolite of sulfadiazine. N(4)-acetylsulfadiazine : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a pyrimidin-2-yl group at the nitrogen atom. It is a metabolite of the drug sulfadiazine. | 2.15 | 1 | 0 | acetamides; pyrimidines; sulfonamide | marine xenobiotic metabolite |
| 4-nitro-alpha-acetylamino-beta-hydroxypropiophenone 4-nitro-alpha-acetylamino-beta-hydroxypropiophenone: inhibitory agent for the differentiation of mammalian tuberculosis strains from other Mycobacteria | 2.15 | 1 | 0 | ||
| formetamide formetamide: RN given refers to cpd with unspecified isomeric designation | 2.15 | 1 | 0 | ||
| isbufylline isbufylline: RN from Toxlit | 2.15 | 1 | 0 | ||
| phenylacetylglycine phenylacetylglycine : A N-acylglycine that is glycine substituted on nitrogen with a phenylacetyl group. | 2.15 | 1 | 0 | monocarboxylic acid amide; monocarboxylic acid; N-acylglycine | human metabolite; mouse metabolite |
| N-benzoylanthranilic acid N-benzoylanthranilic acid : An amidobenzoic acid comprising benzoic acid having a benzamido group at the 2-position. | 2.15 | 1 | 0 | amidobenzoic acid | |
| butinoline [no description available] | 2.15 | 1 | 0 | diarylmethane | |
| n-(2-carboxyphenyl)glycine [no description available] | 2.15 | 1 | 0 | ||
| n,n-dimethyl-4-anisidine [no description available] | 2.15 | 1 | 0 | ||
| n-benzoylpiperidine [no description available] | 2.15 | 1 | 0 | benzamides; N-acylpiperidine | |
| 2-phenylcyclopropanecarboxylic acid 2-phenylcyclopropanecarboxylic acid: RN given for (trans)-isomer; structure in first source | 2.15 | 1 | 0 | ||
| n-demethylantipyrine [no description available] | 2.15 | 1 | 0 | pyrazoles; ring assembly | |
| 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine [no description available] | 2.15 | 1 | 0 | 1,2,4-triazines | |
| 2-amino-5-bromopyridine [no description available] | 2.15 | 1 | 0 | ||
| n-benzoylalanine, (dl-ala)-isomer [no description available] | 2.15 | 1 | 0 | alanine derivative; N-acyl-amino acid | metabolite |
| bicinchoninic acid [no description available] | 2.15 | 1 | 0 | ||
| betamipron [no description available] | 2.15 | 1 | 0 | organonitrogen compound; organooxygen compound | |
| benzoylpropionic acid benzoylpropionic acid: structure in first source. 4-oxo-4-phenylbutyric acid : A 4-oxo monocarboxylic acid that is butyric acid bearing oxo and phenyl substituents at position 4. | 2.15 | 1 | 0 | 4-oxo monocarboxylic acid | hapten |
| Evoxine [no description available] | 2.15 | 1 | 0 | organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle | |
| 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid: precursor of mutagenic nitroso cpd in soy sauce; structure given in first source | 2.15 | 1 | 0 | harmala alkaloid | |
| N-Benzylphthalimide [no description available] | 2.15 | 1 | 0 | isoindoles | |
| pyromellitic diimide pyromellitic diimide: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| 4'-bromosalicylanilide 4'-bromosalicylanilide: photoproduct from UV-irradiation of tribromsalan; structure | 2.15 | 1 | 0 | ||
| 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane: methoxychlor metabolite | 2.15 | 1 | 0 | bisphenol | |
| terephthalamide [no description available] | 2.15 | 1 | 0 | benzenedicarboxamide | |
| 3(2h)-pyridazinone, 4-chloro-5-(dimethylamino)-2-phenyl- [no description available] | 2.15 | 1 | 0 | ||
| 2-nitrophenylacetic acid (2-nitrophenyl)acetic acid : A member of the class of phenylacetic acids that is phenylacetic acid in which the phenyl grup is substituted at the ortho- position by a nitro group. | 2.15 | 1 | 0 | C-nitro compound; phenylacetic acids | |
| onychine [no description available] | 2.15 | 1 | 0 | ||
| 4'-methoxyflavone 4'-methoxyflavone: from seeds of Psoralea corylifolia (Fabaceae); structure in first source | 2.15 | 1 | 0 | ether; flavonoids | |
| 1,3-diphenyl-2-aminopropane 1,3-diphenyl-2-aminopropane: structure given in the first source | 2.15 | 1 | 0 | ||
| 2,2-diphenylpropionic acid 2,2-diphenylpropionic acid: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| 3,4-dimethoxyphenylacetamide 3,4-dimethoxyphenylacetamide: structure | 2.15 | 1 | 0 | ||
| 2-amino-5-bromobenzoic acid 2-amino-5-bromobenzoic acid: structure in first source | 2.15 | 1 | 0 | ||
| 2-(1H-benzimidazol-2-yl)aniline 2-(1H-benzimidazol-2-yl)aniline : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a 2-aminophenyl group at position 2. | 2.15 | 1 | 0 | benzimidazoles; primary arylamine; substituted aniline | geroprotector |
| N-Acetylhomoveratrylamine [no description available] | 2.15 | 1 | 0 | acetamides | |
| 2-chlorobenzenesulfonamide [no description available] | 2.15 | 1 | 0 | ||
| 4-nitrophenyl dimethylcarbamate [no description available] | 2.15 | 1 | 0 | ||
| 8-(4-tolylsulfonylamino)quinoline 8-(4-tolylsulfonylamino)quinoline: has diabetogenic properties; can be used for fluorometric determination of zinc; structure given in first source | 2.15 | 1 | 0 | sulfonamide | |
| 5-methoxyindole-3-carbaldehyde [no description available] | 2.15 | 1 | 0 | indoles | |
| 2-oxo-1,2-dihydroquinoline-4-carboxylic acid [no description available] | 2.15 | 1 | 0 | quinolinemonocarboxylic acid | |
| 6-methoxy-2,3,4,9-tetrahydropyrido[3,4-b]indol-1-one [no description available] | 2.15 | 1 | 0 | beta-carbolines | |
| pd 147953 [no description available] | 2.15 | 1 | 0 | ||
| fenozan fenozan: do not confuse with the phenothiazine phenosan | 2.15 | 1 | 0 | ||
| 5-phenylbarbituric acid 5-phenylbarbituric acid: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| diethylpropion hydrochloride diethylpropion hydrochloride : The hydrochloride salt of diethylpropion. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as an anoretic in the short term management of obesity. | 2.15 | 1 | 0 | hydrochloride | appetite depressant |
| 1-(4'-nitrophenyl)-2-aminopropane-1,3-diol 1-(4'-nitrophenyl)-2-aminopropane-1,3-diol: chloramphenicol minus dichloroacetamide side chain; RN given refers to cpd without isomeric designation | 2.15 | 1 | 0 | ||
| beta-hydroxyphenylalanine beta-hydroxyphenylalanine: RN given refers to beta cpd | 2.15 | 1 | 0 | ||
| 3-(n-salicyloyl)amino-1,2,4-triazole 3-(N-salicyloyl)amino-1,2,4-triazole: synthetic chelating agent used chiefly to inhibit corrosion of copper | 2.15 | 1 | 0 | ||
| 7-chloro-4-aminoquinoline 7-chloro-4-aminoquinoline: structure given in first source | 2.15 | 1 | 0 | aminoquinoline | |
| acridine-9-carboxylic acid [no description available] | 2.15 | 1 | 0 | ||
| 1-phenazinecarboxylic acid 1-phenazinecarboxylic acid: from Streptomyces cinnamonensis; RN given refers to parent cpd; structure given in first source. phenazine-1-carboxylic acid : An aromatic carboxylic acid that is phenazine substituted at C-1 with a carboxy group. | 2.15 | 1 | 0 | aromatic carboxylic acid; monocarboxylic acid; phenazines | antifungal agent; antimicrobial agent; bacterial metabolite |
| 4,5-diphenyl-1,5-dihydroimidazol-2-one [no description available] | 2.15 | 1 | 0 | stilbenoid | |
| 2-hydroxy-1,2-bis(methoxyphenyl)ethanone 2-hydroxy-1,2-bis(methoxyphenyl)ethanone: structure given in first source | 2.15 | 1 | 0 | ||
| 4-methyl-N-(phenylmethyl)benzenesulfonamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-n-butylaminobenzoic acid 4-n-butylaminobenzoic acid: degradation product of tetracaine. 4-(butylamino)benzoic acid : 4-Aminobenzoic acid in which one of the hydrogens attached to the nitrogen is substituted by a butyl group. | 2.15 | 1 | 0 | aromatic amino acid | |
| fluoren-9-ol [no description available] | 2.15 | 1 | 0 | ||
| 1-(2-carboxyethyl)uracil [no description available] | 2.15 | 1 | 0 | ||
| 1-benzylindole 1-benzylindole: structure | 2.15 | 1 | 0 | ||
| 2,3-bis(2-pyridinyl)quinoxaline [no description available] | 2.15 | 1 | 0 | quinoxaline derivative | |
| 3,3',5,5'-tetrachlorobiphenyl-4,4'-diol 3,3',5,5'-tetrachlorobiphenyl-4,4'-diol : A member of the class of hydroxybiphenyls formed formally by chlorination of biphenyl-4,4'-diol at C-3, -3', -5 and -5'. | 2.15 | 1 | 0 | dichlorobenzene; hydroxybiphenyls | |
| 5-nitro-2-(1-piperidinyl)pyridine [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 2-amino-5,7-dimethyl-1,8-naphthyridine 2-amino-5,7-dimethyl-1,8-naphthyridine: structure in first source | 2.15 | 1 | 0 | ||
| 5-benzyloxytryptophan [no description available] | 2.15 | 1 | 0 | ||
| 2,5-diethoxy-4-morpholinoaniline 2,5-diethoxy-4-morpholinoaniline: structure in first source | 2.15 | 1 | 0 | ||
| 3-hydroxy-3-phenacyloxindole [no description available] | 2.15 | 1 | 0 | ||
| carbobenzoxyphenylalanine, (dl-phe)-isomer [no description available] | 2.15 | 1 | 0 | ||
| gamma-fagarine gamma-fagarine: active alkaloid of Chinese medicines from Dictamni radicis cortex (Rutaceae); structure given in first source | 2.15 | 1 | 0 | organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle | |
| 3-carboxymethyl-6-benzyl-2,5-diketopiperazine 3-carboxymethyl-6-benzyl-2,5-diketopiperazine: formed in aqueous solution by aspartame; structure given in first source | 2.15 | 1 | 0 | organonitrogen compound; organooxygen compound | |
| 4-fluorobenzenesulfonamide 4-fluorobenzenesulfonamide: structure given in first source | 2.15 | 1 | 0 | ||
| emoxypine succinate emoxypine succinate: has antihypoxic effects | 2.15 | 1 | 0 | ||
| n-carbamyltryptophan N-carbamyltryptophan: RN given refers to (D)-isomer | 2.15 | 1 | 0 | ||
| 2,4,6-trimethoxyacetophenone 2,4,6-trimethoxyacetophenone: structure in first source | 2.15 | 1 | 0 | ||
| 1-(2-hydroxyethyl)-3,5-diphenyl-1h-pyrazole 1-(2-hydroxyethyl)-3,5-diphenyl-1H-pyrazole: structure given in first source | 2.15 | 1 | 0 | ||
| 4-methyoxybenzoyl-n-glycine [no description available] | 2.15 | 1 | 0 | N-acylglycine | |
| 5-ethoxy-2-ethylmercaptobenzimidazole 5-ethoxy-2-ethylmercaptobenzimidazole: has activating effect on peritoneal macrophages; RN given does not give position for ethoxy group | 2.15 | 1 | 0 | ||
| 5(6)-1(2h)-phthalazinonyl-4(1h)-benzimidazole-2-carbamate methyl ester [no description available] | 2.15 | 1 | 0 | ||
| n-phenyliminodiacetic acid [no description available] | 2.15 | 1 | 0 | ||
| teomorfolin teomorfolin: structure given in first source | 2.15 | 1 | 0 | ||
| 1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)-1-propanone [no description available] | 2.15 | 1 | 0 | benzodioxoles | |
| n-(aminocarbonyl)-2-chlorobenzenesulfonamide [no description available] | 2.15 | 1 | 0 | ||
| 3-hydroxy-2-quinoxalinepropionic acid [no description available] | 2.15 | 1 | 0 | ||
| 8-(methylsulfonylamino)quinoline 8-(methylsulfonylamino)quinoline: has diabetogenic properties; structure given in first source | 2.15 | 1 | 0 | ||
| n(4)-acetylsulfamonomethoxine N(4)-acetylsulfamonomethoxine: main urinary metabolite of sulfamonomethoxine in pigs | 2.15 | 1 | 0 | ||
| 8-(4-benzenesulfonylamino)quinoline 8-(4-benzenesulfonylamino)quinoline: has diabetogenic properties; structure given in first source | 2.15 | 1 | 0 | ||
| methindione methindione: used in treatment of epilepsy; RN given refers to parent cpd; structure | 2.15 | 1 | 0 | ||
| 3,4-dihydroxybenzophenone 3,4-dihydroxybenzophenone: structure in first source | 2.15 | 1 | 0 | ||
| gamma-propanol [no description available] | 2.15 | 1 | 0 | ||
| 2-[(3-oxo-1-cyclohexenyl)amino]benzonitrile [no description available] | 2.15 | 1 | 0 | benzenes; nitrile | |
| isonicotinylamide gaba [no description available] | 2.15 | 1 | 0 | ||
| 5-fluorotryptamine monohydrochloride [no description available] | 2.15 | 1 | 0 | ||
| 4-iodo-n-(2-(4-morpholinyl)ethyl)benzamide 4-iodo-N-(2-(4-morpholinyl)ethyl)benzamide: the iodinated analog of moclobemide; structure given in first source | 2.15 | 1 | 0 | ||
| 3-(hydroxyacetyl)indole 3-(hydroxyacetyl)indole: structure in first source | 2.15 | 1 | 0 | indoles | |
| n-(4-aminophenylsulfonyl)morpholine compound 82 208: structure given in first source | 2.15 | 1 | 0 | ||
| 1H-indol-3-yl-(4-methoxyphenyl)methanone [no description available] | 2.15 | 1 | 0 | N-acylindole | |
| 2-amino-5-phenyl-1,3,4-thiadiazole 2-amino-5-phenyl-1,3,4-thiadiazole: structure in first source | 2.15 | 1 | 0 | ||
| N-(1-phenylethyl)acetamide N-(1-phenylethyl)acetamide : A member of the class of acetamides resulting from the formal condensation of the amino group of 1-phenylethylamine with 1 mol eq. of acetic acid. | 2.15 | 1 | 0 | acetamides; secondary carboxamide | |
| alpha-(trichloromethyl)-4-pyridineethanol alpha-(trichloromethyl)-4-pyridineethanol: activates caspase-3 | 2.15 | 1 | 0 | pyridines | |
| ml 204 ML 204: modulates both TRPC4 and TRPC5 channels; structure in first source | 2.15 | 1 | 0 | ||
| eudesmin eudesmin: RN refers to (1R-(1alpha,3aalpha,4alpha,6aalpha))-isomer; structure given in first source; very similar to pinoresinol | 2.15 | 1 | 0 | ||
| 2-amino-4-methyl-3-nitropyridine [no description available] | 2.15 | 1 | 0 | ||
| 4,4-bis(hydroxymethyl)-2-phenyl-2-oxazoline 4,4-bis(hydroxymethyl)-2-phenyl-2-oxazoline: Anticonvulsant | 2.15 | 1 | 0 | ||
| n-acetylhistidine [no description available] | 2.15 | 1 | 0 | histidine derivative; N-acetyl-amino acid | |
| 1-(1-oxo-2-phenylethyl)-4-piperidinecarboxylic acid [no description available] | 2.15 | 1 | 0 | acetamides | |
| 1-(4-chlorophenyl)-3-(2-ethoxyphenyl)urea [no description available] | 2.15 | 1 | 0 | ureas | |
| 4-methoxyxanthone 4-methoxyxanthone: a vasodilator; structure in first source | 2.15 | 1 | 0 | ||
| N-(4-nitrophenyl)-2-phenoxyacetamide [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 1-phenylindolin-2-one 1-phenylindolin-2-one: structure in first source | 2.15 | 1 | 0 | ||
| 1-(benzenesulfonyl)indole [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 2,4,4,6-Tetramethyl-1,4-dihydro-3,5-pyridinedicarbonitrile [no description available] | 2.15 | 1 | 0 | dihydropyridine | |
| pifithrin mu 2-phenylacetylenesulfonamide: induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia cells; also inhibits Hsp70 and autophagy | 2.15 | 1 | 0 | benzenes | |
| 2-benzyloxybenzaldehyde [no description available] | 2.15 | 1 | 0 | ||
| 2-guanidine-4-methylquinazoline 2-guanidine-4-methylquinazoline: structure given in first source | 2.15 | 1 | 0 | ||
| N-phenylcarbamic acid 2-phenoxyethyl ester [no description available] | 2.15 | 1 | 0 | carbamate ester | |
| 3,4-dihydro-2H-benzo[4,5]imidazo[2,1-b][1,3]thiazin-3-ol [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| mequindox Mequindox: a synthetic quinoxaline 1,4-dioxide derivative which can effectively improve growth and feed efficiency in animals; structure in first source | 2.15 | 1 | 0 | ||
| N-[2-(dimethylamino)ethyl]-2,2-diphenylacetamide [no description available] | 2.15 | 1 | 0 | diarylmethane | |
| Girgensonine [no description available] | 2.15 | 1 | 0 | nitrile | |
| Dubinidine [no description available] | 2.15 | 1 | 0 | organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle | |
| N-[4-(methanesulfonamido)phenyl]acetamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-(2-oxazolo[4,5-b]pyridinyl)aniline [no description available] | 2.15 | 1 | 0 | 1,3-oxazoles | |
| 2-[(4-nitrophenyl)methylthio]-1,3-benzoxazole [no description available] | 2.15 | 1 | 0 | benzoxazole | |
| 3-oxido-4,5-dihydro-[1,2,5]oxadiazolo[3,4-f]cinnolin-3-ium [no description available] | 2.15 | 1 | 0 | pyridazines | |
| 3-(2,4-difluoroanilino)-5,5-dimethyl-1-cyclohex-2-enone [no description available] | 2.15 | 1 | 0 | substituted aniline | |
| 1-phenyl-4-pyrazolol [no description available] | 2.15 | 1 | 0 | pyrazoles; ring assembly | |
| 3-(3,5-dimethyl-1-pyrazolyl)-1,2-benzothiazole 1,1-dioxide [no description available] | 2.15 | 1 | 0 | benzothiazoles | |
| 3-benzamido-2-benzofurancarboxamide [no description available] | 2.15 | 1 | 0 | benzofurans | |
| N-[2-(4-methoxyphenyl)ethyl]acetamide [no description available] | 2.15 | 1 | 0 | acetamides | |
| N-[2-(3-methylphenoxy)ethyl]-1H-1,2,4-triazole-5-carboxamide [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 3-bromo-N-[2-(4-nitroanilino)ethyl]benzamide [no description available] | 2.15 | 1 | 0 | carbonyl compound; organohalogen compound | |
| 3-Methylbenzofuran-2-carboxylic acid [no description available] | 2.15 | 1 | 0 | benzofurans | |
| 5-(3,4-dimethoxyphenyl)-2H-tetrazole [no description available] | 2.15 | 1 | 0 | tetrazoles | |
| 1-(4-fluorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| 4-[[bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol [no description available] | 2.15 | 1 | 0 | alkylbenzene | |
| 2-phenylindole-3-carbaldehyde 2-phenylindole-3-carbaldehyde: structure in first source | 2.15 | 1 | 0 | ||
| 4-(2-pyridinylthio)benzofuro[3,2-d]pyrimidine [no description available] | 2.15 | 1 | 0 | aryl sulfide | |
| 5-(4-nitrophenyl)-4-phenyl-2-thiazolamine [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 3-[6-(4-aminophenyl)-2-phenyl-4-pyrimidinyl]aniline [no description available] | 2.15 | 1 | 0 | pyrimidines | |
| 7-methoxyisoflavone 7-methoxyisoflavone : A methoxyisoflavone that is isoflavone substituted by a methoxy group at position 7. | 2.15 | 1 | 0 | 7-methoxyisoflavones | |
| LSM-32392 [no description available] | 2.15 | 1 | 0 | monoterpenoid | |
| N-[2-(1-cyclohexenyl)ethyl]-4-(4-morpholinylmethyl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1-(1-benzimidazolyl)-3-(1-cyclohex-3-enylmethoxy)-2-propanol [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| N-[2-(2-furanylmethylthio)ethyl]-4-methoxybenzenesulfonamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 3-acetamido-5-chloro-2-benzofurancarboxylic acid [no description available] | 2.15 | 1 | 0 | benzofurans | |
| [4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-(2,6-dimethoxyphenyl)methanone [no description available] | 2.15 | 1 | 0 | dimethoxybenzene | |
| 4-[4-methyl-6-(4-methyl-1-piperazinyl)-2-pyrimidinyl]morpholine [no description available] | 2.15 | 1 | 0 | N-arylpiperazine | |
| haplamine haplamine: isolated from Haplophyllum acutifolium; structure in first source | 2.15 | 1 | 0 | organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle | |
| 5-(3,4-dimethoxyphenyl)-1H-1,2,4-triazol-3-amine [no description available] | 2.15 | 1 | 0 | triazoles | |
| 2-ethoxy-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 2-[(5-methyl-1H-1,2,4-triazol-3-yl)thio]-1-phenylethanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 1-ethyl-6-methoxy-4-oxo-3-quinolinecarboxylic acid [no description available] | 2.15 | 1 | 0 | quinolines | |
| 2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline 2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline : A member of the class of quinazolines that is quinazoline which is substituted at positions 2 and 4 by pyridin-4-yl and pyrrolidin-1-yl groups, respectively. | 2.15 | 1 | 0 | pyridines; pyrrolidines; quinazolines | |
| scp 1 [no description available] | 2.15 | 1 | 0 | ||
| N-(3-acetamidophenyl)-4-methoxybenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-(3-acetamidophenyl)-3-chlorobenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 4-methoxy-N-(5-methyl-3-isoxazolyl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-(2-fluorophenyl)-4-phenylmethoxybenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-[4-(diethylamino)phenyl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| N-(2-furanylmethyl)-2-benzofurancarboxamide [no description available] | 2.15 | 1 | 0 | benzofurans | |
| 5-(2-phenylethyl)-1,3,4-thiadiazol-2-amine [no description available] | 2.15 | 1 | 0 | aromatic amine; thiadiazoles | |
| te 5 [no description available] | 2.15 | 1 | 0 | ||
| 2-[[anilino(oxo)methyl]amino]-4,5-dimethyl-3-thiophenecarboxamide [no description available] | 2.15 | 1 | 0 | ureas | |
| N-(4,6-dimethyl-2-pyrimidinyl)-1,3-benzothiazol-2-amine [no description available] | 2.15 | 1 | 0 | benzothiazoles | |
| 6-methylflavone 6-methylflavone: structure in first source | 2.15 | 1 | 0 | ||
| 2-methoxy-N-(2-pyridinyl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 2-chloro-N-(2-phenylethyl)benzamide [no description available] | 2.15 | 1 | 0 | carbonyl compound; organohalogen compound | |
| N1-(4H-1,2,4-triazol-4-yl)-4-nitrobenzamide [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| N-[2-(1-cyclohexenyl)ethyl]-4-fluorobenzamide [no description available] | 2.15 | 1 | 0 | carbonyl compound; organohalogen compound | |
| tioxazafen tioxazafen : A 1,2,4-oxadizole in which the hydrogens at positions 3 and 5 have been replaced by phenyl and thiophen-2-yl groups, respectively. It is used as a broad spectrum nematicidal seed treatment. | 2.15 | 1 | 0 | 1,2,4-oxadiazole; thiophenes | agrochemical; nematicide |
| N-[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]-2-thiophen-2-ylacetamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| 1-(4-Methoxyphenyl)-2-nitroethylene 4-methoxy-beta-nitrostyrene: has vasodilator activity; structure in first source | 2.15 | 1 | 0 | methoxybenzenes | |
| brd32048 BRD32048: inhibits ETV1 oncoprotein; structure in first source | 2.15 | 1 | 0 | methoxybenzenes; substituted aniline | |
| 2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 2-(3,4-dichlorophenyl)imidazo[1,2-a]pyrimidine [no description available] | 2.15 | 1 | 0 | imidazoles | |
| 5-(2-phenyl-4-triazolyl)-2H-tetrazole [no description available] | 2.15 | 1 | 0 | triazoles | |
| N-cyclohexyl-2,3-dihydroindole-1-carboxamide [no description available] | 2.15 | 1 | 0 | indolyl carboxylic acid | |
| 4-(benzylsulfanyl)thieno[2,3-d]pyrimidine 4-(benzylsulfanyl)thieno[2,3-d]pyrimidine : A thienopyrimidine that is thieno[2,3-d]pyrimidine which is substituted at position 4 by a benzylsulfanediyl group. | 2.15 | 1 | 0 | aryl sulfide; benzenes; thienopyrimidine | |
| 2-methyl-5-(5-methyl-2-furanyl)-3-(1-pyrrolyl)-4-thieno[2,3-d]pyrimidinone [no description available] | 2.15 | 1 | 0 | organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound | |
| 1-[2-(dimethylamino)ethyl]-5-methoxy-N-methyl-2-indolecarboxamide [no description available] | 2.15 | 1 | 0 | indolecarboxamide | |
| N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-methoxybenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 4-(1H-benzimidazol-2-yl)quinoline [no description available] | 2.15 | 1 | 0 | quinolines | |
| 1-(4-Chlorophenyl)-2-[(1-methyl-1H-imidazol-2-yl)thio]ethan-1-one [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| N-(2,5-dimethylphenyl)-2-benzofurancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| N-(4-methoxyphenyl)-2-benzofurancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 2-(9h-xanthen-9-yl)-malonic acid [no description available] | 2.15 | 1 | 0 | xanthenes | |
| 1-(1,3-benzothiazol-2-yl)-3-phenylurea [no description available] | 2.15 | 1 | 0 | ureas | |
| 1-hydroxy-2-phenyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one [no description available] | 2.15 | 1 | 0 | imidazoles | |
| N-(4-acetamidophenyl)-2-bromobenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 4-bromo-N-phenacylbenzamide [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 1-(2,3-dihydroindol-1-yl)-2-(phenylthio)ethanone [no description available] | 2.15 | 1 | 0 | indoles | |
| N-[6-methyl-2-(4-methylphenyl)-5-benzotriazolyl]-3-pyridinecarboxamide [no description available] | 2.15 | 1 | 0 | triazoles | |
| N,N-dimethyl-N'-p-tolylsulfamide N,N-dimethyl-N'-p-tolylsulfamide : A member of the class of sulfamides that is N,N-dimethylsulfuric diamide substituted by a 4-methylphenyl group at the amino nitrogen atom. It is a metabolite of the agrochemical tolylfluanid. | 2.15 | 1 | 0 | sulfamides | marine xenobiotic metabolite |
| 2-(1-piperidinylmethyl)phenol 2-(1-piperidinylmethyl)phenol: structure in first source | 2.15 | 1 | 0 | ||
| 2,6-bis(benzimidazol-2-yl)pyridine 2,6-bis(benzimidazol-2-yl)pyridine: structure in first source | 2.15 | 1 | 0 | benzimidazoles | |
| 1-cyclohexyl-3-(2-phenylethyl)urea [no description available] | 2.15 | 1 | 0 | benzenes | |
| 1-(3,5-dichlorophenyl)-3-phenylurea [no description available] | 2.15 | 1 | 0 | ureas | |
| 1-(cyclohexylmethyl)-4-phenylpiperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| N-phenethyl-2-furamide [no description available] | 2.15 | 1 | 0 | aromatic amide; heteroarene | |
| paromomycin sulfate [no description available] | 2.15 | 1 | 0 | ||
| N,N,2-trimethyl-1-phenyl-5-benzimidazolesulfonamide [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| N-(phenylmethyl)-4-(3-pyridinyl)-2-thiazolamine [no description available] | 2.15 | 1 | 0 | aralkylamine | |
| N-(4-hydroxy-2-methyl-5-propan-2-ylphenyl)benzenesulfonamide [no description available] | 2.15 | 1 | 0 | monoterpenoid | |
| 2-amino-5-ethyl-4-(2-furanyl)-6-propyl-3-pyridinecarbonitrile [no description available] | 2.15 | 1 | 0 | nitrile; pyridines | |
| 2-ethoxy-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| vu0099704 VU0099704: an antagonist of protease activated receptor 4 (PAR-4); structure in first source | 2.15 | 1 | 0 | ||
| 3-(4-chlorophenyl)-2,5-dimethyl-1H-pyrazolo[1,5-a]pyrimidin-7-one [no description available] | 2.15 | 1 | 0 | pyrazoles; ring assembly | |
| 1-(2-chloro-6-fluorophenyl)-[1,2,4]triazolo[4,3-a]quinoline [no description available] | 2.15 | 1 | 0 | triazoles | |
| 2-methyl-N-(1-methyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)propanamide [no description available] | 2.15 | 1 | 0 | pyrroloquinoline | |
| 2-methyl-5-[(2-methyl-4-quinolinyl)thio]-1,3,4-thiadiazole [no description available] | 2.15 | 1 | 0 | aryl sulfide | |
| 5-methyl-1-(4-nitrophenyl)-2-oxo-2,5-dihydro-1h-pyrido(3,2-b)indole-3-carbonitrile VRX-413638: structure in first source | 2.15 | 1 | 0 | ||
| (3-hydroxy-5,6,7,8-tetrahydro-4H-cyclohepta[d]imidazol-2-yl)-phenylmethanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 2-fluoro-N-phenacylbenzamide [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 4-(methoxymethyl)-6-methyl-2-(2-methylanilino)-3-pyridinecarbonitrile [no description available] | 2.15 | 1 | 0 | nitrile; pyridines | |
| 1-azepanyl-[2-methoxy-4-(methylthio)phenyl]methanone [no description available] | 2.15 | 1 | 0 | carbonyl compound; thiol | |
| GS4012 free base GS4012 free base : A member of the class of pyridines that is 2-(pyridin-4-yl)ethane-1-thiol in which the thiol hydrogen is replaced by a 4-methoxyphenyl group. | 2.15 | 1 | 0 | aryl sulfide; monomethoxybenzene; pyridines | VEGF activator |
| N-[1-(4-methylphenyl)-5-benzimidazolyl]acetamide [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| 2-(4-methylanilino)-1-(4-nitrophenyl)ethanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide : An amino acid amide obtained by the formal condensation of 2,6-dimethylaniline with N-(3,5-dimethylphenyl)glycine. | 2.15 | 1 | 0 | amino acid amide; glycine derivative | |
| 2-[4-[(3-fluorophenyl)methyl]-1-piperazinyl]pyrimidine [no description available] | 2.15 | 1 | 0 | N-arylpiperazine | |
| 1-[(3,4-dimethoxyphenyl)methyl]-4-(2,3-dimethylphenyl)piperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| 4-Piperidinobenzoic acid [no description available] | 2.15 | 1 | 0 | piperidines | |
| 1-(2-methoxyphenyl)-4-(3-thiophenylmethyl)piperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| N-(1-methyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)-2-(1-pyrrolidinyl)acetamide [no description available] | 2.15 | 1 | 0 | pyrroloquinoline | |
| 4-[(1H-benzimidazol-2-ylthio)methyl]-2-thiazolamine [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| 4-[(4-phenyl-2-thiazolyl)amino]benzenesulfonamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| N-[7-(1-oxopropyl)-2,3-dihydro-1,4-benzodioxin-6-yl]benzamide [no description available] | 2.15 | 1 | 0 | benzodioxine | |
| N-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine: an SK channel inhibitor | 2.15 | 1 | 0 | ||
| 8-(3,5-dimethyl-1-pyrazolyl)quinoline [no description available] | 2.15 | 1 | 0 | quinolines | |
| 2'-nitroflavone 2'-nitroflavone: has antineoplastic activity | 2.15 | 1 | 0 | ||
| N-(4-methoxyphenyl)-3,4-dihydroquinolin-2-amine [no description available] | 2.15 | 1 | 0 | aminoquinoline | |
| 1-(3-nitrophenyl)-3-phenyl-2-propyn-1-one [no description available] | 2.15 | 1 | 0 | aromatic compound | |
| vrt 532 VRT 532: a CFTR potentiator; structure in first source | 2.15 | 1 | 0 | ||
| 4-[[4-(2,5-dimethylphenyl)-1-piperazinyl]methyl]-2-methoxyphenol [no description available] | 2.15 | 1 | 0 | piperazines | |
| 1-piperonylpiperidine 1-piperonylpiperidine: an AMPA receptor modulator; structure in first source | 2.15 | 1 | 0 | ||
| 2-[(3-fluorophenyl)methyl-(phenylmethyl)amino]ethanol [no description available] | 2.15 | 1 | 0 | aromatic amine | |
| 2-methoxy-4-[[2-(methylthio)anilino]methyl]phenol [no description available] | 2.15 | 1 | 0 | aromatic amine | |
| 6-ethyl-5-methyl-2-thiophen-2-yl-1H-pyrazolo[1,5-a]pyrimidin-7-one [no description available] | 2.15 | 1 | 0 | pyrazolopyrimidine | |
| N-[4-(2-methyl-4-thiazolyl)phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-(6-phenyl-5-imidazo[2,1-b]thiazolyl)benzamide [no description available] | 2.15 | 1 | 0 | imidazoles | |
| 2-(phenylmethylthio)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole [no description available] | 2.15 | 1 | 0 | aryl sulfide | |
| 5-methyl-N-(4,5,6-trimethyl-2-pyrimidinyl)-1,3-benzoxazol-2-amine [no description available] | 2.15 | 1 | 0 | benzoxazole | |
| 1-(4-methoxyphenyl)-3-(6-methyl-2-pyridinyl)urea [no description available] | 2.15 | 1 | 0 | ureas | |
| 2-{[hydroxy(2-methoxyphenyl)methylidene]amino}acetic acid [no description available] | 2.15 | 1 | 0 | N-acylglycine | |
| (4-methoxyphenyl)-(3-methyl-2-propyl-4-imidazolyl)methanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| N-(3-acetamidophenyl)-2-chlorobenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N4,N4-dimethyl-N1-(4-nitro-1,1-dioxo-2,5-dihydrothiophen-3-yl)benzene-1,4-diamine [no description available] | 2.15 | 1 | 0 | dialkylarylamine; tertiary amino compound | |
| 2-bromo-N-(3-methoxyphenyl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 2-methoxy-4-[(4-methyl-1,4-diazepan-1-yl)methyl]-6-nitrophenol [no description available] | 2.15 | 1 | 0 | aromatic ether; C-nitro compound | |
| 3-[[(2,5-dimethyl-3-furanyl)-oxomethyl]amino]benzoic acid [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 1-(4-ethoxyphenyl)-3-(6-quinoxalinyl)urea [no description available] | 2.15 | 1 | 0 | quinoxaline derivative | |
| 2-(dimethylsulfamoylamino)-9H-fluorene [no description available] | 2.15 | 1 | 0 | fluorenes | |
| 4-chloro-1-ethyl-3-nitro-2-quinolinone [no description available] | 2.15 | 1 | 0 | nitro compound; quinolines | |
| 4-chloro-3-nitro-1-(phenylmethyl)-2-quinolinone [no description available] | 2.15 | 1 | 0 | quinolines | |
| 2,5-dimethyl-1-(phenylmethyl)pyrrole-3,4-dicarboxaldehyde [no description available] | 2.15 | 1 | 0 | arenecarbaldehyde | |
| 2-(2-chloro-6-fluorophenyl)-1-(2,4-dihydroxyphenyl)ethanone [no description available] | 2.15 | 1 | 0 | stilbenoid | |
| 4-methyl-N-(3-nitrophenyl)-5-phenyl-3-thiophenecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| N-(5-amino-1-phenyl-1,2,4-triazol-3-yl)-2,2,2-trichloroacetamide [no description available] | 2.15 | 1 | 0 | triazoles | |
| N-(2-fluoro-5-methylphenyl)-3-phenylpropanamide [no description available] | 2.15 | 1 | 0 | anilide | |
| N-[(4-fluorophenyl)methyl]-2-thiophen-2-ylacetamide [no description available] | 2.15 | 1 | 0 | organofluorine compound | |
| 4-tert-butyl-N-(1,4-dioxo-2,3-dihydrophthalazin-5-yl)benzamide [no description available] | 2.15 | 1 | 0 | phthalazines | |
| N-[2-(2-methylpropyl)-1,3-dioxo-5-isoindolyl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | phthalimides | |
| 6-(1,4,5,7-tetramethyl-6-pyrrolo[3,4-d]pyridazinyl)quinoline [no description available] | 2.15 | 1 | 0 | quinolines | |
| 2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone [no description available] | 2.15 | 1 | 0 | stilbenoid | |
| 5-(3-chloro-4-methylphenyl)-3-pyridin-4-yl-1,2,4-oxadiazole [no description available] | 2.15 | 1 | 0 | oxadiazole; ring assembly | |
| 5-(phenylmethyl)-3-(2-pyridinyl)-1,2,4-oxadiazole [no description available] | 2.15 | 1 | 0 | pyridines | |
| 2-methyl-5-(1-pyrrolidinyl)isoindole-1,3-dione [no description available] | 2.15 | 1 | 0 | phthalimides | |
| (2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine) [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| N-(4-bromo-2-fluorophenyl)-2-methyl-3-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 6,7,8,9-tetrahydro-5H-carbazole-3-carbohydrazide [no description available] | 2.15 | 1 | 0 | carbazoles | |
| N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide [no description available] | 2.15 | 1 | 0 | primary carboxamide; pyrazines; secondary carboxamide | |
| N-(1,3-benzodioxol-5-yl)-5-methyl-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | benzodioxoles | |
| 1-cyclohexyl-3-(2,3-dihydro-1,4-benzodioxin-6-yl)urea [no description available] | 2.15 | 1 | 0 | benzodioxine | |
| 8-[(2-methyl-5-nitro-1,2,4-triazol-3-yl)thio]quinoline [no description available] | 2.15 | 1 | 0 | aryl sulfide | |
| 1-[2-(2-chlorophenoxy)ethyl]benzimidazole [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| 4,5-dimethyl-2-[4-(3-nitrophenyl)-2-thiazolyl]-1H-pyrazol-3-one [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 2-(4-fluoro-N-methylsulfonylanilino)-N-(3-methylphenyl)acetamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 1-(4-fluorophenyl)-2-(2-pyridinylthio)ethanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 3-methyl-6-(1-pyrrolidinyl)-[1,2,4]triazolo[4,3-b]pyridazine [no description available] | 2.15 | 1 | 0 | triazolopyridazine | |
| N-(3-acetylphenyl)-2-thiophen-2-ylacetamide [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| oncrasin-1 oncrasin-1: an antineoplastic agent; structure in first source. oncrasin-1 : A member of the class of indoles that is 1H-indole substituted by 4-chlorobenzyl and formyl groups at positions 1 and 3, respectively. It is an anti-cancer agent that is active against lung cancer cells with K-Ras mutations. | 2.15 | 1 | 0 | arenecarbaldehyde; indoles; monochlorobenzenes | antineoplastic agent; apoptosis inducer |
| N-[2-(4-fluorophenyl)ethyl]-4-nitrobenzamide [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 5-(1-methyl-2-benzimidazolyl)-2-thiophenecarboxaldehyde [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| N-(4-anilinophenyl)-2-methylpropanamide [no description available] | 2.15 | 1 | 0 | anilide | |
| N-(2-fluorophenyl)-3-phenylpropanamide [no description available] | 2.15 | 1 | 0 | anilide | |
| 1-[(Phenylthio)acetyl]piperidine [no description available] | 2.15 | 1 | 0 | N-acylpiperidine | |
| N-(3-hydroxyphenyl)-5-methyl-3-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 3-(4-methoxyphenyl)-5-(4-methylphenyl)-1,2,4-oxadiazole [no description available] | 2.15 | 1 | 0 | oxadiazole; ring assembly | |
| 4-[(4-carboxy-2,6-dimethoxyphenoxy)methyl]-5-methyl-2-furancarboxylic acid [no description available] | 2.15 | 1 | 0 | trihydroxybenzoic acid | |
| 4-(4-morpholinylmethyl)-3-quinolinol [no description available] | 2.15 | 1 | 0 | quinolines | |
| 2-bromo-N-[3-(1-oxopropylamino)phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 3-acetyl-2-methylbenzo[f]benzofuran-4,9-dione [no description available] | 2.15 | 1 | 0 | naphthofuran | |
| 5-(4-chlorophenyl)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; heteroarene | |
| 1-azepanyl-[4-[(phenylthio)methyl]phenyl]methanone [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1-(5-ethyl-2,4-dihydroxyphenyl)-2-(2-fluorophenoxy)ethanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-nitrophenyl)acetamide [no description available] | 2.15 | 1 | 0 | acetamides | |
| 3,4,5-triethoxy-N-(1H-1,2,4-triazol-5-yl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1-propylsulfonyl-4-(2-pyridinyl)piperazine [no description available] | 2.15 | 1 | 0 | piperazines; pyridines | |
| 2-(2-phenylethylthio)-3-pyridinecarboxylic acid [no description available] | 2.15 | 1 | 0 | aromatic carboxylic acid; pyridines | |
| 2-(2,3-dimethylphenoxy)-N-pyridin-4-ylacetamide [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 2-[[anilino(oxo)methyl]amino]-N-(phenylmethyl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-(5-acetyl-4-methyl-2-thiazolyl)-5-bromo-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | thiazoles | |
| 1-cyclohexyl-3-(3-ethylphenyl)urea [no description available] | 2.15 | 1 | 0 | ureas | |
| n-phenylpiracetam N-phenylpiracetam: structure given in first source | 2.15 | 1 | 0 | ||
| 2-[(1-methyl-5-tetrazolyl)thio]-N-(2-phenylphenyl)acetamide [no description available] | 2.15 | 1 | 0 | biphenyls | |
| N-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-nitrobenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-N-(2,6-dimethylphenyl)benzamide [no description available] | 2.15 | 1 | 0 | isoquinolines | |
| 5-(4-bromophenyl)-N-(2-methoxyphenyl)-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 3-[[(3,5-dichloro-4-ethoxyphenyl)-oxomethyl]amino]benzoic acid [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1,4-bis(thiophen-2-ylsulfonyl)piperazine [no description available] | 2.15 | 1 | 0 | N-sulfonylpiperazine; thiophenes | |
| 2-bromo-N-[3-(1-oxobutylamino)phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1-(2-fluorophenyl)-4-[(6-nitro-1,3-benzodioxol-5-yl)methyl]piperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| n-(1-benzyl-4-piperidinyl)-2,4-dichlorobenzamide N-(1-benzyl-4-piperidinyl)-2,4-dichlorobenzamide: inhibits the betaine-GABA transporter 1; structure in first source | 2.15 | 1 | 0 | ||
| 2-[[2-(5-methyl-2-thiophenyl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone [no description available] | 2.15 | 1 | 0 | quinazolines | |
| 1-(2,1,3-benzothiadiazol-5-yl)-3-[4-(4-morpholinyl)phenyl]urea [no description available] | 2.15 | 1 | 0 | morpholines | |
| ethyl 4-{N-[(4-chlorophenyl)sulfonyl]-N-methylglycyl}piperazine-1-carboxylate ethyl 4-{N-[(4-chlorophenyl)sulfonyl]-N-methylglycyl}piperazine-1-carboxylate : A sulfonamide in which the nitrogen carries methyl and 2-[4-(ethoxycarbonyl)piperazin-1-yl]-2-oxoethyl substituents and the sulfonyl a 4-chlorophenyl group. | 2.15 | 1 | 0 | carbamate ester; sulfonamide | |
| LSM-4563 [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 1-(4-chloro-3-methoxyphenyl)sulfonyl-4-phenylpiperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| N-[4-[(3,4-dimethoxyphenyl)sulfamoyl]phenyl]acetamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-chloro-3-(1-piperidinylsulfonyl)-N-(2-thiazolyl)benzamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 1-(2,5-dimethoxyphenyl)sulfonyl-4-(phenylmethyl)piperazine [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 2-(4-methoxyphenyl)-N-[4-[(5-methyl-3-isoxazolyl)sulfamoyl]phenyl]acetamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-[4-(benzenesulfonyl)-1-piperazinyl]-2-methylquinoline [no description available] | 2.15 | 1 | 0 | piperazines; pyridines | |
| 1-(6-methoxy-2,2,4-trimethyl-1-quinolinyl)-2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone [no description available] | 2.15 | 1 | 0 | quinolines | |
| N2-phenyl-6-[[(1-phenyl-5-tetrazolyl)thio]methyl]-1,3,5-triazine-2,4-diamine [no description available] | 2.15 | 1 | 0 | tetrazoles | |
| 2-[(4,6-dimethyl-2-pyrimidinyl)thio]-N-(4,5-diphenyl-2-oxazolyl)acetamide [no description available] | 2.15 | 1 | 0 | 1,3-oxazoles | |
| 2-(4-bromophenyl)-1-[4-(2-pyridinyl)-1-piperazinyl]ethanone [no description available] | 2.15 | 1 | 0 | piperazines; pyridines | |
| 2-amino[1,3]thiazolo[4,5-d]pyrimidine-5,7-diol [no description available] | 2.15 | 1 | 0 | thiazolopyrimidine | |
| 3-[[(2-cyclohexyl-1,3-dioxo-5-isoindolyl)-oxomethyl]amino]benzoic acid [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| 3-[[[3-(1-azepanylsulfonyl)-4-chlorophenyl]-oxomethyl]amino]benzoic acid [no description available] | 2.15 | 1 | 0 | benzamides | |
| 2-(4-bromophenyl)-N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)acetamide [no description available] | 2.15 | 1 | 0 | acetamides | |
| 5-(1,3-benzodioxol-5-ylsulfamoyl)-2-methoxybenzoic acid [no description available] | 2.15 | 1 | 0 | methoxybenzoic acid | |
| N-cycloheptyl-1-(4-methylphenyl)sulfonyl-4-piperidinecarboxamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 3-(2-chlorophenyl)-5-methyl-N-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-4-isoxazolecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| N-[3-[[(4-nitrophenyl)-oxomethyl]amino]phenyl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 3-methyl-1,5-dithiophen-2-ylpentane-1,5-dione [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| N-(2-methyl-1,3-benzothiazol-6-yl)-4-(4-morpholinylsulfonyl)benzamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-(dimethylsulfamoyl)-N-(4-thiophen-2-yl-2-thiazolyl)benzamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 3-chloro-N-[4-[(1-oxo-2-phenylethyl)amino]phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-(3,4-dimethoxyphenyl)-4-[(4-phenyl-1-piperazinyl)methyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| stk295900 [no description available] | 2.15 | 1 | 0 | ||
| 1-(3-chlorophenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]piperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| 2-[4-[[4-(4-methoxyphenyl)-1-phthalazinyl]amino]phenyl]acetamide [no description available] | 2.15 | 1 | 0 | pyridazines; ring assembly | |
| 1-(2-fluorophenyl)-3-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]urea [no description available] | 2.15 | 1 | 0 | ureas | |
| N-[5-[(4-methoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | methoxybenzenes | |
| N-(1,3-benzodioxol-5-yl)-4-methyl-1-phthalazinamine [no description available] | 2.15 | 1 | 0 | phthalazines | |
| SMER 28 SMER 28 : A member of the class of quinazolines that is quinazoline which is substituted by a prop-2-en-1-ylnitrilo group and a bromo group at positions 4 and 6, respectively. It is a modulator of mammalian autophagy. | 2.15 | 1 | 0 | organobromine compound; quinazolines; secondary amino compound | autophagy inducer |
| N-[4-(4-morpholinyl)phenyl]carbamic acid butyl ester [no description available] | 2.15 | 1 | 0 | morpholines | |
| 4-(4-chlorophenoxy)-1-(4-morpholinyl)-1-butanone [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 4-(4-chlorophenoxy)-1-(1-piperidinyl)-1-butanone [no description available] | 2.15 | 1 | 0 | N-acylpiperidine | |
| N-(3-phenylpropyl)methanesulfonamide [no description available] | 2.15 | 1 | 0 | benzenes | |
| 4-acetamido-N-(2-methoxyethyl)benzamide [no description available] | 2.15 | 1 | 0 | amidobenzoic acid | |
| 2-methyl-N-(2,3,4,5,6-pentafluorophenyl)-3-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 3,4-dihydro-2H-quinolin-1-yl-(4-propoxyphenyl)methanone [no description available] | 2.15 | 1 | 0 | quinolines | |
| 5-bromo-N-(2-phenylphenyl)-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 2-[2-(4-chlorophenoxy)ethylthio]pyrimidine [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 3-(3-bromoanilino)-1-(5-methyl-2-furanyl)-1-propanone [no description available] | 2.15 | 1 | 0 | aralkylamine | |
| 4-[2-(4-bromo-2-chlorophenoxy)-1-oxoethyl]-1-piperazinecarboxylic acid ethyl ester [no description available] | 2.15 | 1 | 0 | piperazinecarboxylic acid | |
| 2-[2-[[3-(1,3-benzoxazol-2-yl)anilino]-oxomethyl]phenyl]benzoic acid [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1-[2-(2-chlorophenoxy)ethoxy]-2-methoxy-4-methylbenzene [no description available] | 2.15 | 1 | 0 | methoxybenzenes | |
| N-[4-[(4-sulfamoylphenyl)sulfamoyl]phenyl]cyclopropanecarboxamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-[2-[2-(4-bromo-2-chlorophenoxy)ethoxy]ethyl]morpholine [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| N-[2-(2-phenylphenoxy)ethyl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | biphenyls | |
| 5,6,7,8-tetrafluoro-2-(2,3,4,5,6-pentafluorophenyl)-4h-1-benzopyran-4-one 5,6,7,8-tetrafluoro-2-(2,3,4,5,6-pentafluorophenyl)-4H-1-benzopyran-4-one: structure in first source | 2.15 | 1 | 0 | ||
| 2-[bis(5-methyl-2-furanyl)methyl]-6-nitrophenol [no description available] | 2.15 | 1 | 0 | nitrophenol | |
| 2-(4-nitrophenyl)-N-(2-oxolanylmethyl)-4-quinazolinamine [no description available] | 2.15 | 1 | 0 | quinazolines | |
| 2-(4-hydroxy-1,3-thiazol-2-yl)-1-phenylethan-1-one [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| Methyl(2-furoylamino)acetic acid [no description available] | 2.15 | 1 | 0 | N-acyl-amino acid | |
| 5-nitro-8-(1-pyrrolidinyl)quinoline [no description available] | 2.15 | 1 | 0 | nitro compound; quinolines | |
| 2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide [no description available] | 2.15 | 1 | 0 | amino acid amide | |
| 2-[(4-methylphenyl)sulfonylamino]pentanoic acid [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4,6-dimorpholino-n-(4-nitrophenyl)-1,3,5-triazin-2-amine 4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine: an mTOR activator; structure in first source | 2.15 | 1 | 0 | ||
| 1-[(3-chlorophenyl)methyl]-N,N-diethyl-3-piperidinecarboxamide [no description available] | 2.15 | 1 | 0 | piperidines | |
| 1-(2,6-dimethyl-1-piperidinyl)-2-phenylethanone [no description available] | 2.15 | 1 | 0 | acetamides | |
| 2-amino-7-methyl-5-oxo-4-(2,3,4-trimethoxyphenyl)-4,6,7,8-tetrahydro-1-benzopyran-3-carbonitrile [no description available] | 2.15 | 1 | 0 | methoxybenzenes | |
| 3-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-1-phenylpyrrolidine-2,5-dione [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 1-(4-bromophenyl)-3-(diethylamino)pyrrolidine-2,5-dione [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 4-(5,6-diphenyl-1,2,4-triazin-3-yl)morpholine [no description available] | 2.15 | 1 | 0 | dialkylarylamine; tertiary amino compound | |
| (3,5-Dimethyl-1-adamantyl)amine nitrate [no description available] | 2.15 | 1 | 0 | nitrates | |
| 1-(4-tert-butylphenoxy)-3-(1H-1,2,4-triazol-5-ylthio)-2-propanol [no description available] | 2.15 | 1 | 0 | alkylbenzene | |
| N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-2-adamantanamine [no description available] | 2.15 | 1 | 0 | N-alkylpyrrolidine | |
| 4-phenyl-N-(pyridin-4-ylmethyl)-2-butanamine [no description available] | 2.15 | 1 | 0 | aralkylamine | |
| N-(5-nitro-2-pyridinyl)cyclopropanecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| 3-[(4-bromophenyl)methyl]-4-(4-methoxyanilino)-4-oxobutanoic acid [no description available] | 2.15 | 1 | 0 | anilide | |
| 3-ethyl-N-(2H-tetrazol-5-yl)-1-adamantanecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| N-(4-propan-2-ylphenyl)-3-bicyclo[2.2.1]heptanecarboxamide [no description available] | 2.15 | 1 | 0 | monoterpenoid | |
| 4-chloro-N-[2-(4-nitroanilino)ethyl]benzamide [no description available] | 2.15 | 1 | 0 | carbonyl compound; organohalogen compound | |
| 2-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-oxomethyl]-1-cyclohexanecarboxylic acid [no description available] | 2.15 | 1 | 0 | benzodioxine | |
| 2,4-dichloro-6-[1-(4-morpholinyl)-3-phenylprop-2-ynyl]phenol [no description available] | 2.15 | 1 | 0 | aromatic compound | |
| 2-[[1-(4-ethoxyphenyl)-2,5-dioxo-3-pyrrolidinyl]amino]acetonitrile [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 1-ethoxy-3-(2-methoxy-4-prop-2-enylphenoxy)-2-propanol [no description available] | 2.15 | 1 | 0 | methoxybenzenes | |
| 6-amino-4-(3-chlorophenyl)-3-methyl-1-(phenylmethyl)-4H-pyrano[2,3-c]pyrazole-5-carbonitrile [no description available] | 2.15 | 1 | 0 | organochlorine compound; pyranopyrazole | |
| 1-(2-chlorophenoxy)-3-(2-methyl-1-benzimidazolyl)-2-propanol [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide [no description available] | 2.15 | 1 | 0 | hydroxyquinoline | |
| N-(2-hydroxy-5-methylphenyl)-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 4-amino-7,8,9,10-tetrahydro-6H-pyrimido[3,4]pyrrolo[3,5-a]azepine-11-carbonitrile [no description available] | 2.15 | 1 | 0 | organic heterobicyclic compound; organonitrogen heterocyclic compound | |
| 1-(3,5-dimethylphenyl)-3-(1H-1,2,4-triazol-5-ylthio)pyrrolidine-2,5-dione [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 6-[(3,4-difluoroanilino)-oxomethyl]-1-cyclohex-3-enecarboxylic acid [no description available] | 2.15 | 1 | 0 | anilide | |
| 4-[(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)amino]-4-oxobutanoic acid [no description available] | 2.15 | 1 | 0 | organosulfur heterocyclic compound | |
| [3-methyl-4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-thiophen-2-ylmethanone [no description available] | 2.15 | 1 | 0 | aromatic amide; thiophenes | |
| [4-(2-methoxyphenyl)-1-piperazinyl]-[4-[(phenylthio)methyl]phenyl]methanone [no description available] | 2.15 | 1 | 0 | piperazines | |
| N-(3,3,5-trimethylcyclohexyl)-1H-1,2,4-triazole-5-carboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; heteroarene | |
| 4-[2-nitro-5-[4-(phenylmethyl)sulfonyl-1-piperazinyl]phenyl]morpholine [no description available] | 2.15 | 1 | 0 | piperazines | |
| 5-(4-ethylsulfonyl-1-piperazinyl)-2-nitro-N-(3-pyridinylmethyl)aniline [no description available] | 2.15 | 1 | 0 | piperazines | |
| 2-[[5-[(1,3-benzothiazol-2-ylthio)methyl]-4-methyl-1,2,4-triazol-3-yl]thio]-N-[2-(4-morpholinyl)ethyl]acetamide [no description available] | 2.15 | 1 | 0 | benzothiazoles | |
| N-ethyl-N-[2-[(5-nitro-8-quinolinyl)amino]ethyl]benzenesulfonamide [no description available] | 2.15 | 1 | 0 | nitro compound; quinolines | |
| 1-(4-methoxyphenyl)-N-(4-methyl-2-pyridinyl)-5-oxo-3-pyrrolidinecarboxamide [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 3,4,5-trimethoxy-N-[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene BRL-50481 : A C-nitro compound that is benzene substituted by N,N-dimethylaminosulfonyl, methyl and nitro groups at positions 1, 2 and 5, respectively. It is a phosphodiesterase inhibitor selective for the PDE7 subtype (Ki = 180 nM). | 2.15 | 1 | 0 | C-nitro compound; sulfonamide; toluenes | bone density conservation agent; EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor; geroprotector |
| 6,3',4'-Trimethoxyflavanone [no description available] | 2.15 | 1 | 0 | ether; flavonoids | |
| 1-[4-(3-ethoxyphenoxy)butyl]imidazole [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 5-[[(1-cyclohexyl-5-tetrazolyl)thio]methyl]-3-phenyl-1,2,4-oxadiazole [no description available] | 2.15 | 1 | 0 | oxadiazole; ring assembly | |
| 2-[1-(3,4-dihydro-2H-quinolin-1-yl)-1-oxopropan-2-yl]isoindole-1,3-dione [no description available] | 2.15 | 1 | 0 | phthalimides | |
| [4-(benzenesulfonyl)-1-piperazinyl]-(1-piperidinyl)methanone [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 3-(2,5-dioxo-1-pyrrolidinyl)-N-(2-methyl-1,3-dioxo-5-isoindolyl)benzamide [no description available] | 2.15 | 1 | 0 | amidobenzoic acid | |
| 6-[[[5-(ethylthio)-1,3,4-thiadiazol-2-yl]amino]-oxomethyl]-1-cyclohex-3-enecarboxylic acid [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| 2,5-dimethoxy-n-(quinolin-3-yl)benzenesulfonamide 2,5-dimethoxy-N-(quinolin-3-yl)benzenesulfonamide: a tissue-nonspecific alkaline phosphatase inhibitor; structure in first source | 2.15 | 1 | 0 | quinolines | |
| LSM-25805 [no description available] | 2.15 | 1 | 0 | isoindoles | |
| 4-ethoxy-N-(3-quinolinyl)benzenesulfonamide [no description available] | 2.15 | 1 | 0 | quinolines | |
| 3-chloro-N-[3-(1-imidazolyl)propyl]-6-nitro-1-benzothiophene-2-carboxamide [no description available] | 2.15 | 1 | 0 | 1-benzothiophenes | |
| nsc 727447 NSC 727447: structure in first source | 2.15 | 1 | 0 | ||
| 2-methoxy-N-[(4-methylphenyl)methyl]-2-phenylacetamide [no description available] | 2.15 | 1 | 0 | acetamides | |
| 2-(4-chlorophenoxy)-N-(5-nitro-2-thiazolyl)acetamide [no description available] | 2.15 | 1 | 0 | C-nitro compound; thiazoles | |
| 7-(2-methoxyphenyl)-5-phenyl-1,7-dihydrotetrazolo[1,5-a]pyrimidine [no description available] | 2.15 | 1 | 0 | methoxybenzenes | |
| N-[3-[2,5-dioxo-3-(phenylmethyl)-1-pyrrolidinyl]phenyl]acetamide [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 3,4-dimethoxy-N-[3-(methylthio)phenyl]benzenesulfonamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 3-methyl-4-nitro-N-(1H-1,2,4-triazol-5-yl)benzamide [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 2-[(4-chlorophenyl)methylthio]-N-(2-hydroxy-5-nitrophenyl)acetamide [no description available] | 2.15 | 1 | 0 | nitrophenol | |
| 2-(4-ethoxyphenyl)-N-[3-(1-imidazolyl)propyl]-4-quinolinecarboxamide [no description available] | 2.15 | 1 | 0 | quinolines | |
| N-(4-bromophenyl)-5-methyl-4-nitro-1H-pyrazol-3-amine [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-2h-indol-2-one 3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-2H-indol-2-one: an estrogen receptor alpha inhibitor | 2.15 | 1 | 0 | ||
| N-[4-[(cyclohexylamino)-oxomethyl]phenyl]-3-pyridinecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| N,N,4-trimethyl-2-[[(5-methyl-2-furanyl)-oxomethyl]amino]-5-thiazolecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; thiazoles | |
| ex 527 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine. | 2.15 | 1 | 0 | carbazoles; monocarboxylic acid amide; organochlorine compound | |
| 3-[3-[(5-ethyl-[1,2,4]triazino[5,6-b]indol-3-yl)thio]propyl]-1H-benzimidazol-2-one [no description available] | 2.15 | 1 | 0 | indoles | |
| 4-methyl-2,7-diphenyl-8H-pyrido[2,3-d]pyrimidin-5-one [no description available] | 2.15 | 1 | 0 | phenylpyridine | |
| 3-methylharman [no description available] | 2.15 | 1 | 0 | ||
| 1-methyl-beta-carboline-3-carboxylic acid 1-methyl-beta-carboline-3-carboxylic acid: metabolite from cows fed with corn silage; structure in first source | 2.15 | 1 | 0 | ||
| sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position. | 2.15 | 1 | 0 | piperazines; pyrazolopyrimidine; sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent |
| 2-methyl-4(3h)-quinazolinone 2-methyl-4(3H)-quinazolinone: from Bacillus cereus; structure given in first source | 2.15 | 1 | 0 | ||
| n(4)-desoxychlordiazepoxide N(4)-desoxychlordiazepoxide: not phototoxic; structure given in first source | 2.15 | 1 | 0 | ||
| 2-amino-3-hydroxyphenazine 2-amino-3-hydroxyphenazine: structure given in first source | 2.15 | 1 | 0 | ||
| 2-styrylquinazolin-4(3h)-one 2-styrylquinazolin-4(3H)-one: structure given in first source | 2.15 | 1 | 0 | ||
| 2-amino-5-iodo-6-phenyl-4-pyrimidinone [no description available] | 2.15 | 1 | 0 | ||
| quininib quininib: has antiangiogenic activity; structure in first source. quininib : A styrylquinoline that is trans-2-styrylquinoline in which the the phenyl group has been substituted at position 2 by a hydroxy group. It is an anti-angiogenic compound that exerts a dose-dependent antagonism of the cysteinyl leukotriene pathway, preferentially antagonising cysteinyl leukotriene receptor 1. The major species at pH 7.3 | 2.15 | 1 | 0 | phenols; styrylquinoline | angiogenesis inhibitor |
| bropirimine [no description available] | 2.15 | 1 | 0 | pyrimidines | |
| 2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-1H-quinazolin-4-one [no description available] | 2.15 | 1 | 0 | quinazolines | |
| 2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-6-(methoxymethyl)-1H-pyrimidin-4-one [no description available] | 2.15 | 1 | 0 | quinazolines |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Innate Inflammatory Response [description not available] | 0 | 2.05 | 1 | 0 |
| Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. | 0 | 2.05 | 1 | 0 |
| Encephalitis, Polio [description not available] | 0 | 2.06 | 1 | 0 |
| Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5) | 0 | 2.06 | 1 | 0 |
| Plasmodium falciparum Malaria [description not available] | 0 | 2.1 | 1 | 0 |
| Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations. | 0 | 2.1 | 1 | 0 |
| Anemia, Fanconi [description not available] | 0 | 2.13 | 1 | 0 |
| Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004) | 0 | 2.13 | 1 | 0 |